X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    New Delivery Path Brings To Light Efficacy of Immunotherapy

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    New Delivery Path Brings To Light Efficacy of Immunotherapy

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Europe

Ground-breaking joint-working project in which public & voluntary sectors collaborated with UCB to deliver improved epilepsy services in Dumfries & Galloway receives recognition of the Scottish Parliament

Yuvraj_pawp by Yuvraj_pawp
18th March 2016
in Europe, Projects

A ground-breaking collaborative project, driven by Epilepsy Scotland, together with two pharmaceutical companies, to develop and improve epilepsy services for adults in Dumfries & Galloway, was today recognised at the Scottish Parliament.

The story of the transformation of care for epilepsy patients in the region, which includes the creation of specialist nursing posts and care plans for patients, has been documented in a report, “A Cross-Sector Joint Working Model to Evaluate and Improve Services for People with Epilepsy in the Dumfries & Galloway Health Board Area1, was unveiled at a reception in Holyrood.

The report which contains the findings and outcomes of the project was presented to MSPs, the Cross Party Group on Epilepsy, Health Care Professionals (HCPs) and the media. Guest speakers at the event included the Minister for Health Improvement in Scotland, Jamie Hepburn.

The project was enabled by a joint-working agreement between Epilepsy Scotland, NHS Dumfries & Galloway (NHS D&G), UCB and GlaxoSmithKline. Under the agreement, each partner contributed equally, either financially or in kind, to improve epilepsy services in the area through the appointment of a part-time Epilepsy Specialist Nurse (ESN), who was also qualified in learning disabilities. Over a three-year period, the ESN worked with consultants, nursing staff, GPs, Practice Nurses and other local healthcare professionals to provide advice and training, develop tools for epilepsy care and advise patients and carers.

The successful outcome of this initiative has resulted in the appointment of a permanent/full time ENS for the estimated 1,500 epilepsy patients in D&G as well as the part-time ENS, with both posts now funded by NHS D&G.

The NHS Dumfries & Galloway Health Board includes 34 practices, serving a population of 150,000. The catalyst for the project came in 2010, when the local patient support group, appealed for an epilepsy specialist nurse and expressed their concern over the non-existence of a permanent specialist neurologist in the region.

The audit work of the report which examined the treatment of 168 patients uncovered many areas for improvement in epilepsy services for patients including:

  • 50% had no record of who had diagnosed their epilepsy
  • 7% had no record of seizure classification
  • 44% had no care plan
  • Only 43% had been given advice regarding pregnancy
  • Only 8% had received information regarding SUDEP (sudden death in epilepsy)
  • Only 1% had been signposted to further support such as that offered by a patient group.

The project has gone on to deliver significant service improvements including:

  • Accelerated access to medical treatment from a trained specialist epilepsy nurse (patients had previously to wait several months to access a visiting neurologist)
  • Training in epilepsy for GP’s and practice nurses
  • Hand held patient records
  • Tool kits for training NHS staff

Patients assisted and encouraged to seek further help from patient support and other organisations to help manage their condition and get their lives back on track Medication and care plan reviews in accordance with national guidance.

Steve Turley, MD UCB BII said, “Our determination to make the project a success helped us overcome a number of challenges, not least of which was communicating with everyone so that we all worked together. Being the first of its kind within the UK, the business model for the project presented uncharted challenges for the companies – all driving towards the same goal, improving care. Critical to the success of the project was benchmarking and gathering feedback to maximise the benefits of the specialist nursing post.”

The project has created a role model for change for the better in epilepsy services in Scotland and has the potential to be used in other health areas.

Epilepsy is a chronic neurological condition affecting 1 in every 97 people in Scotland, meaning there are approximately 55,000 people living with this condition in the nation. Around 1 in 5 people with epilepsy also have a learning disability. This condition is characterised by transient bursts of abnormal electrical activity in the brain, known as seizures, which can lead to a wide range of temporary symptoms including loss of consciousness, involuntary muscle contractions, and mood changes. Not surprisingly, the unpredictable nature of seizures and the stigma often associated with epilepsy can have a major impact on all aspects of a person’s life, as well as the quality of life of family members and caregivers.

Epilepsy Scotland’s Chief Executive Lesslie Young said, “This novel collaboration between the public, private and voluntary sector sets a new benchmark in joint working for better healthcare and has led to a project that is unique in the UK. As this is an original model of cascading epilepsy expertise, the process has not been without its challenges. However, the end result of this cross-sector partnership, means hundreds of people will have a better quality of care and direct access to local epilepsy services.”

Tags: Europe
Previous Post

Inovio Signs Collaborative Research Agreements

Next Post

Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering RAVICTI(R) (glycerol phenylbutyrate) Oral Liquid

Related Posts

Pharmapack 2023 a pivotal moment for sustainability in drug delivery and packaging
Europe

Pharmapack 2023 a pivotal moment for sustainability in drug delivery and packaging

3rd March 2023
Dr Reddy's Lab gets DCGI nod for Sputnik Phase 2 & 3 trials
Europe

RDIF and Minapharm Agree to Produce over 40 Million Doses of the Sputnik V Vaccine in Egypt

26th April 2021
Sputnik V: World's First COVID-19 Vaccine Now Available to Public in Russia
Europe

Sputnik V: World’s First COVID-19 Vaccine Now Available to Public in Russia

26th September 2020
AstraZeneca agrees to supply Europe with 400 million doses of COVID-19 vaccine
Europe

Valneva Announces Major COVID-19 Vaccine Partnership with U.K. Government

21st September 2020
Europe

Pharmintech 2019: Big increase in International Participation Expected

18th November 2018
Europe

Novo Nordisk acquires Ziylo Ltd to accelerate its development of glucose responsive insulins

17th August 2018
Next Post

Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering RAVICTI(R) (glycerol phenylbutyrate) Oral Liquid

Latest News

Drug Development

New Delivery Path Brings To Light Efficacy of Immunotherapy

1st April 2023
Cathay Cargo signs global airline partnership with Tower Cold Chain
Packaging & Logistic

Cathay Cargo signs global airline partnership with Tower Cold Chain

31st March 2023
Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

£277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In